- Prof. Wilbert S. Aronow, MD, FACC, FAHA
- Westchester Medical Center and New York Medical College, Valhalla, NY 10595, USA.
Website | E-mail
Special Issue Introduction
SGLT2 inhibitors reduce in patients with type 2 diabetes mellitus major adverse cardiovascular events and progression of chronic kidney disease. These drugs also reduce heart failure and cardiovascular death in patients with heart failure and reduced left ventricular ejection fraction. A meta-analysis demonstrated that SGLT2 inhibitors decrease the risk of heart failure hospitalization by 32%, cardiovascular death by 17%, and all-cause mortality by 15%. Ongoing clinical trials are investigating the use of SGLT2 inhibitors in the treatment of patients with and without diabetes mellitus heart failure and preserved left ventricular ejection fraction, heart failure and reduced left ventricular ejection fraction, and chronic kidney disease.
KeywordsSGLT2 inhibitors; empagliflozin; canagliflozin; dapagliflozin; diabetes mellitus; heart failure; chronic kidney disease
Submission Deadline30 Sep 2020